Allergan Announces FDA Approval of Rhofade (oxymetazoline hydrochloride) Cream for Facial Erythema Associated with Rosacea

DUBLIN, Jan. 19, 2017 /PRNewswire/ — Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today the approval of Rhofade cream by the U.S. Food and Drug Administration (FDA) for the topical treatment of persistent facial…

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us